Banner
The Official News & Technical Journal Of The International Society For Pharmacoeconomics And Outcomes Research

Coming Soon!

Value & Outcomes Spotlight
A Journal of The International Society
for Pharmacoeconomics and Outcomes Research

A full-color new publication featuring expanded content
on health policy and methodological issues of relevance
to the ISPOR membership.

To receive ISPOR CONNECTIONS, a bimonthly news & technical journal,
Join ISPOR.

Articles are available in PDF and html format. All PDF formats accessible for members only.
Red Bulletdenotes items accessible for members only

Latest Issue
PRESIDENT'S MESSAGE
Reflections from Amsterdam

METHODOLOGY
Considerations When Meta-Analyzing Diagnostic Test Sensitivity and Specificity When an Adequate Reference Standard ExistsRed Bullet
In this article, Wolowacz et al. examine common issues related to the measurement of health state utility values for economic models in clinical trials, and introduce the work of the ISPOR Task Force which is developing best practice guidelines.

Electronic Clinical Outcomes Assessments (eCOAs). How Long Do They Take to Complete and How Burdensome are they for Patients?Red Bullet
In this article, AbuDagga and colleagues use data from the 2007 National Home and Hospice Care Survey to describe a cultural competency training (CCT) provision scale and examine the role of organizational and leadership factors on the adoption of CCT.

HEALTH POLICY
The Value of Oncology Therapies and Emerging Access Hurdles: Germany, Canada, and the United StatesRed Bullet
This article from Lee et al. details an inquiry into recent value paradigm shifts and emerging market access and reimbursement hurdles in oncology in three key countries–Germany, Canada, and the US–and identifies what can be learned from the evolving landscape for developing access strategies and value propositions.

How (Not) To Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDs): Recommendations from the URD Evaluation Project Red Bullet
Michael Schlander and colleagues report on an expert consensus recommending that the evaluation of drugs for ultra-rare disorders (URDs) should insist on strong evidence of clinical benefits, whereas meaningful economic analysis may require an entirely new evaluation paradigm, capturing social value beyond the aggregation of individual health gains valued by individual preferences.

LETTER FROM THE EDITOR
Letter from the Editor

ISPOR IN ACTION
The International Society for Pharmacoeconomics and Outcomes Research New CEO and Executive Director-Nancy S. Berg
ISPOR 17th Annual European Congress-New Challenges, New Frontiers!
ISPOR 17th European Congress Photo Gallery
ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award Presentation and Recipient Remarks: Martin Buxton and Bengt Jönsson, PhD
ISPOR 20th International Meeting Call for Abstracts
ISPOR 5th Latin America Conference Call for Abstracts

STUDENT CORNER
Connection and Collaboration: Student Activities at the ISPOR 17th Annual European Congress

ISPOR CONNECTIONS Vol.19 No. 6

[ Past Issue PDFs ]